Hutchmed stock
Web11 apr. 2024 · HUTCHMED (China) Limited heeft aangekondigd dat Dr. Karen Jean Ferrante de Onderneming heeft meegedeeld dat zij zich bij de komende jaarlijkse algemene vergadering van de Onderneming op 12 mei 2024 zal terugtrekken uit de Raad en dat zij zich niet herkiesbaar zal stellen op de jaarlijkse algemene vergadering zodat zij meer tijd … Web13 apr. 2024 · 2 Wall Street research analysts have issued 1-year price objectives for HUTCHMED's shares. Their HCM share price forecasts range from GBX 100 to GBX …
Hutchmed stock
Did you know?
Web3 apr. 2024 · As of April 3, 2024, HUTCHMED (China) Ltd (ADR)’s stock price is $12.46, which is down 4.3% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Web12 apr. 2024 · 3 Wall Street analysts have issued 12-month price targets for HUTCHMED's stock. Their HCM share price forecasts range from $16.00 to $16.00. On average, they …
WebFind the latest HUTCHMED (China) Limited (HCM.L) stock quote, history, news and other vital information to help you with your stock trading and investing. Web12 apr. 2024 · Press Release HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2024 Hong Kong, Shanghai & Florham Park, NJ - Wednesday, April 12, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non …
WebHUTCHMED (CHINA) LIMITED HCM Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals London Stock … Web4 apr. 2024 · Hutchmed (China) Limited 04 April 2024 Press Release HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and... 11/04/2024 14:09:46 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. Monitor; Quote; ... Aquis Stock Exchange: Ordinary Share: KYG4672N1198 Price Change % Change Share Price Bid …
Web30 mrt. 2024 · Hutchmed Stock Price Today (NASDAQ: HCM) Quote, Market Cap, Chart WallStreetZen Hutchmed Ltd Stock Add to Watchlist Overview Earnings Dividend Ownership $13.64 -0.17 (-1.23%) Updated Mar 28, 2024 1W - 9.07% 1M - 17.58% 3M - 7.02% 1Y - 26.59% HCM Price $13.64 Fair Value Price $15.81 Market Cap $2.36B 52 …
Web10 apr. 2024 · The upgrade of HUTCHMED to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might … sunova group melbourneWeb11 apr. 2024 · HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2024. HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated … sunova flowWeb11 apr. 2024 · HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. sunova implementWeb6 apr. 2024 · Get HUTCHMED (China) Ltd (13-HK:Hong Kong Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. sunpak tripods grip replacementWebHutchmed Stock Forecast FAQ. What is HCM's forecast return on equity (ROE) for 2024-2026? (NASDAQ: HCM) forecast ROE is N/A, which is considered weak.If you're new to stock investing, here's how to buy Hutchmed stock. What is HCM's forecast return on assets (ROA) for 2024-2026? su novio no saleWeb6 apr. 2024 · HUTCHMED (China) Ltd ( HCM) is near the top in its industry group according to InvestorsObserver. HCM gets an overall rating of 72. That means it scores higher than 72 percent of stocks. HUTCHMED (China) Ltd gets a 96 rank in the Drug Manufacturers - Specialty & Generic industry. sunova surfskateWeb6 apr. 2024 · Hutchmed stock rises 15% as fruquintinib meets one main goal in gastric cancer trial SA News Mon, Nov. 14, 2024 Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder sunova go web